SOPHiA GENETICS (SOPH) Set to Announce Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) is set to release its earnings data before the market opens on Tuesday, May 7th. Analysts expect SOPHiA GENETICS to post earnings of ($0.28) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, March 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.12). SOPHiA GENETICS had a negative return on equity of 47.40% and a negative net margin of 126.63%. The firm had revenue of $17.05 million during the quarter, compared to the consensus estimate of $16.78 million. During the same period in the prior year, the company posted ($0.22) EPS. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $5.00 on Monday. The stock’s 50 day moving average is $4.93 and its 200 day moving average is $4.55. SOPHiA GENETICS has a twelve month low of $2.13 and a twelve month high of $7.37.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. BTIG Research increased their price target on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a report on Wednesday, March 6th.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.